You have reached the legacy site. Please visit our new site at

 Google Custom Search
Zerit (d4T, stavudine)

Articles on Zerit
Full US Prescribing Information

Zerit is in a category of HIV medications called nucleoside reverse transcriptase inhibitors (NRTIs).

Zerit, manufactured by Bristol-Myers Squibb, was approved by the U.S. Food and Drug Administration for the treatment of HIV in 1994.

Articles on Zerit

FDA Updates Label Information for Stavudine (Zerit)

Benefits versus Risks of Stavudine (Zerit) Therapy for HIV-related Neurological Complications

Longer Exposure to NRTIs, especially Stavudine (Zerit), Increases the Risk of Insulin Resistance in Women with HIV

Long-term Fat Loss among Treatment-naive Patients Starting Combination Therapy Containing Stavudine (Zerit), Zidovudine (Retrovir), or Abacavir (Ziagen)

What Is the Impact on Lipoatrophy and Dyslipidemia of Reducing the Dose of d4T (Zerit) Compared with Switching to Tenofovir (Viread)?